Approaches like that might hold the answer for detecting peptides better in the future
The evidence supporting lipotropic injections themselves remains limited and of low quality
Oral Vitamin B12 versus Intramuscular Vitamin B12 for Vitamin B12 Deficiency. Cochrane Database of Systematic Reviews, no

Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome

Obese Zucker rats treated with AOD-9604 at 500 mcg/kg/day for 19 days showed a statistically significant reduction in body fat compared to vehicle-treated controls